Our vision is to significantly change the practice of oncology by developing medicines that provide truly meaningful improvements in quality of life and survival for people with cancer.

Our wholly-owned deep pipeline includes six differentiated and novel investigational oncology therapeutic candidates that target some of the most critical pathways that cancer cells use to grow. We were founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco.